Xinxiang Tuoxin Pharmaceutical Co.Ltd.
Tuoxin Pharmaceutical Group Co.,Ltd. engages in the research and development, production and sales of nucleoside (acid) APIs and pharmaceutical intermediates in China. It offers nucleoside (acid) products, such as pyrimidine series, purine series, and nucleotide series; nucleoside series, including citicoline sodium, ribavirin, inosine, acyclovir, azithromycin, cytosine, 5-fluorocytosine, cytidin… Read more
Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089) - Total Assets
Latest total assets as of June 2025: CN¥1.71 Billion CNY
Based on the latest financial reports, Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089) holds total assets worth CN¥1.71 Billion CNY as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Xinxiang Tuoxin Pharmaceutical Co.Ltd. - Total Assets Trend (2019–2024)
This chart illustrates how Xinxiang Tuoxin Pharmaceutical Co.Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Xinxiang Tuoxin Pharmaceutical Co.Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s total assets of CN¥1.71 Billion consist of 38.5% current assets and 61.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 3.9% |
| Accounts Receivable | CN¥78.59 Million | 4.5% |
| Inventory | CN¥178.88 Million | 10.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥81.83 Million | 4.7% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s current assets represent 38.5% of total assets in 2024, a decrease from 41.9% in 2019.
- Cash Position: Cash and equivalents constituted 3.9% of total assets in 2024, down from 14.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 9.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 10.2% of total assets.
Xinxiang Tuoxin Pharmaceutical Co.Ltd. Competitors by Total Assets
Key competitors of Xinxiang Tuoxin Pharmaceutical Co.Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Xinxiang Tuoxin Pharmaceutical Co.Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Xinxiang Tuoxin Pharmaceutical Co.Ltd. generates 0.24x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Xinxiang Tuoxin Pharmaceutical Co.Ltd. is currently not profitable relative to its asset base.
Xinxiang Tuoxin Pharmaceutical Co.Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.75 | 4.63 | 3.38 |
| Quick Ratio | 3.33 | 3.54 | 2.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥500.91 Million | CN¥ 576.33 Million | CN¥ 558.32 Million |
Xinxiang Tuoxin Pharmaceutical Co.Ltd. - Advanced Valuation Insights
This section examines the relationship between Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.37 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | -4.4% |
| Total Assets | CN¥1.76 Billion |
| Market Capitalization | $223.17 Million USD |
Valuation Analysis
Below Book Valuation: The market values Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s assets below their book value (0.13 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s assets decreased by 4.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Xinxiang Tuoxin Pharmaceutical Co.Ltd. (2019–2024)
The table below shows the annual total assets of Xinxiang Tuoxin Pharmaceutical Co.Ltd. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.76 Billion | -4.39% |
| 2023-12-31 | CN¥1.84 Billion | -0.23% |
| 2022-12-31 | CN¥1.84 Billion | +32.26% |
| 2021-12-31 | CN¥1.39 Billion | +47.25% |
| 2020-12-31 | CN¥946.48 Million | +27.93% |
| 2019-12-31 | CN¥739.85 Million | -- |